
Joanne Edwards

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5837875/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	THEM6â€mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 2022, 14, e14764.	3.3	12
2	Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 2022, , .	2.9	2
3	Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer. Clinical Science, 2022, 136, 521-535.	1.8	4
4	The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 2022, 127, 1-11.	1.1	2
5	The Relationship Between the Tumor Cell Expression of Hypoxic Markers and Survival in Patients With ER-positive Invasive Ductal Breast Cancer. Journal of Histochemistry and Cytochemistry, 2022, 70, 479-494.	1.3	4
6	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 2021, 124, 786-796.	2.9	11
7	The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress. Cell Death and Differentiation, 2021, 28, 1563-1578.	5.0	19
8	MNK Inhibition Sensitizes <i>KRAS</i> -Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	7.7	45
9	Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2021, 7, 121-134.	1.3	17
10	The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103231.	2.0	20
11	The inflammatory microenvironment in screen-detected premaligant adenomatous polyps: early results from the integrated technologies for improved polyp surveillance (INCISE) project. European Journal of Gastroenterology and Hepatology, 2021, 33, 983-989.	0.8	3
12	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	5.0	13
13	The relationship between β-catenin and patient survival in colorectal cancer systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103337.	2.0	8
14	Novel Methods of Risk Stratifying Patients for Metachronous, Pre-Malignant Colorectal Polyps: A Systematic Review. Critical Reviews in Oncology/Hematology, 2021, 164, 103421.	2.0	5
15	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 2021, 16, 163.	1.2	9
16	Systematic review of tumour budding and association with common mutations in patients with colorectal cancer. Critical Reviews in Oncology/Hematology, 2021, 167, 103490.	2.0	3
17	Preoperative, biopsyâ€based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 30-39.	1.3	11
18	Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer. Cancer Research, 2020, 80, 576-590.	0.4	26

#	Article	IF	CITATIONS
19	BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 2020, 39, 1797-1806.	2.6	10
20	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. Biomolecules, 2020, 10, 1365.	1.8	22
21	The effect of postoperative complications on survival and recurrence after surgery for breast cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 155, 103075.	2.0	13
22	Determining the prognostic significance of IKKÎ $_{\pm}$ in prostate cancer. Prostate, 2020, 80, 1188-1202.	1.2	5
23	Gut Î ³ δT cells as guardians, disruptors, and instigators of cancer. Immunological Reviews, 2020, 298, 198-217.	2.8	28
24	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naÃ ⁻ ve prostate cancer. Prostate, 2020, 80, 1353-1364.	1.2	4
25	Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 596-606.	2.0	7
26	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 2020, 6, 283-296.	1.3	17
27	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. Cancer Research, 2020, 80, 2325-2339.	0.4	21
28	Local immune response in colon cancer: Indicative of good or poor prognosis?. Journal of Clinical Oncology, 2020, 38, 213-213.	0.8	0
29	The relationship between members of the canonical NF-kB pathway, tumour microenvironment and cancer specific survival in colorectal cancer patients. Histology and Histopathology, 2020, 35, 569-578.	0.5	1
30	The role of gamma delta T lymphocytes in breast cancer: a review. Translational Research, 2019, 203, 88-96.	2.2	46
31	A novel tumorâ€based epithelialâ€toâ€mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. International Journal of Cancer, 2019, 144, 150-159.	2.3	28
32	The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 4397-4404.	0.7	47
33	Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer. Cellular Signalling, 2019, 56, 15-22.	1.7	38
34	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clinical Science, 2019, 133, 181-193.	1.8	51
35	The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer. Cellular Signalling, 2019, 60, 91-99.	1.7	7
36	A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 2019, 206, 91-106.	2.2	20

#	Article	IF	CITATIONS
37	Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: Implications for treatment. Cellular Signalling, 2019, 54, 81-90.	1.7	11
38	The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer. International Journal of Cancer, 2019, 144, 2320-2329.	2.3	10
39	The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, R369-R380.	1.6	85
40	The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer Journal of Clinical Oncology, 2019, 37, 581-581.	0.8	1
41	Comorbidity and systemic inflammation are independent prognostic factors in patients with colorectal cancer: A ScotScan collaborative study Journal of Clinical Oncology, 2019, 37, 707-707.	0.8	0
42	The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. British Journal of Cancer, 2018, 118, 705-712.	2.9	46
43	MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 2018, 9, 19.	2.7	134
44	Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial. Journal of the National Cancer Institute, 2018, 110, 616-627.	3.0	8
45	Sprouty2 lossâ€induced IL 6 drives castrationâ€resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 2018, 10, .	3.3	19
46	NF-κB pathways in the development and progression of colorectal cancer. Translational Research, 2018, 197, 43-56.	2.2	164
47	Mannose impairs tumour growth and enhances chemotherapy. Nature, 2018, 563, 719-723.	13.7	282
48	Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient. Scientific Reports, 2018, 8, 14672.	1.6	93
49	Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer― British Journal of Cancer, 2018, 119, 909-909.	2.9	0
50	Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets. Cells, 2018, 7, 176.	1.8	49
51	ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. British Journal of Cancer, 2018, 119, 323-329.	2.9	11
52	Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene, 2018, 37, 4679-4691.	2.6	31
53	The Prognostic Role of the Non-Canonical Nuclear Factor-Kappa B Pathway in Renal Cell Carcinoma Patients. Urologia Internationalis, 2018, 101, 190-196.	0.6	9
54	A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 2017, 130, 697-711.	1.2	19

#	Article	IF	CITATIONS
55	In reply to â€~Hynes <i>etÂal</i> . Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage <scp>II</scp> / <scp>III</scp> colon cancer in a large populationâ€based study'. Histopathology, 2017, 71, 326-327.	1.6	2
56	Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. British Journal of Cancer, 2017, 116, 1444-1450.	2.9	46
57	Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treatment Reviews, 2017, 57, 1-7.	3.4	36
58	High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)â€positive breast cancer. International Journal of Cancer, 2017, 140, 1633-1644.	2.3	22
59	The relationship between oestrogen receptorâ€alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer. Histopathology, 2017, 70, 782-797.	1.6	2
60	Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers. Journal of Medicinal Chemistry, 2017, 60, 7043-7066.	2.9	23
61	Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host. Clinical Cancer Research, 2017, 23, 1698-1709.	3.2	38
62	The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer. Annals of Surgical Oncology, 2017, 24, 1295-1303.	0.7	34
63	Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 2017, 8, 4875-4887.	0.8	14
64	The relationship between members of the canonical NF-κB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 2017, 8, 33002-33013.	0.8	15
65	Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Oncotarget, 2017, 8, 37172-37185.	0.8	6
66	<i>Sleeping Beauty</i> screen reveals <i>Pparg</i> activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8290-8295.	3.3	91
67	Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer. Oncolmmunology, 2016, 5, e1098801.	2.1	29
68	The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. British Journal of Cancer, 2016, 115, 967-973.	2.9	26
69	Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 2016, 16, 229.	1.1	30
70	The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. British Journal of Cancer, 2016, 115, 156-163.	2.9	54
71	Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence. Molecular Carcinogenesis, 2016, 55, 1667-1677.	1.3	12
72	Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. British Journal of Cancer, 2016, 114, 562-570.	2.9	59

#	Article	IF	CITATIONS
73	Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. Oncotarget, 2016, 7, 70601-70612.	0.8	12
74	The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget, 2016, 7, 77607-77621.	0.8	16
75	Signal transduction and activator of transcription 3 (STAT3), host inflammatory responses and survival of patients with colorectal cancer Journal of Clinical Oncology, 2016, 34, 606-606.	0.8	1
76	Elevated LIM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation. Molecular Cancer Therapeutics, 2015, 14, 246-258.	1.9	30
77	The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. British Journal of Cancer, 2015, 113, 1066-1074.	2.9	67
78	Evaluation of a Tumor Microenvironment–Based Prognostic Score in Primary Operable Colorectal Cancer. Clinical Cancer Research, 2015, 21, 882-888.	3.2	69
79	Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e100759.	1.1	80
80	Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer, 2014, 14, 676.	1.1	41
81	CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 2014, 127, 3893-901.	1.2	85
82	RUNX2 in subtype specific breast cancer and mammary gland differentiation. DMM Disease Models and Mechanisms, 2014, 7, 525-34.	1.2	53
83	SIRT2: Tumour suppressor or tumour promoter in operable breast cancer?. European Journal of Cancer, 2014, 50, 290-301.	1.3	78
84	The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer. British Journal of Cancer, 2014, 111, 157-165.	2.9	90
85	The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 231-241.	2.0	63
86	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. European Urology, 2014, 66, 32-39.	0.9	139
87	Abstract 976: Junctional adhesion molecule-A (JAM-A) expression is downmodulated by miR-21 during colorectal cancer progression. , 2014, , .		Ο
88	Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1â€phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptorâ€positive breast cancer. International Journal of Cancer, 2013, 132, 605-616.	2.3	40
89	Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2013, 17, 887-898.	0.9	80
90	IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFβ1-induced mesenchymal invasion. International Journal of Biochemistry and Cell Biology, 2013, 45, 2774-2785.	1.2	26

#	Article	IF	CITATIONS
91	Senescent cells harbour features of the cancer epigenome. Nature Cell Biology, 2013, 15, 1495-1506.	4.6	300
92	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
93	Reclassification of the Fuhrman grading system in renal cell carcinoma-does it make a difference?. SpringerPlus, 2013, 2, 378.	1.2	6
94	The relationship between genetic profiling, clinicopathological factors and survival in patients undergoing surgery for node-negative colorectal cancer: 10-year follow-up. Journal of Cancer Research and Clinical Oncology, 2013, 139, 2013-2020.	1.2	3
95	Interactions between MAP kinase and oestrogen receptor in human breast cancer. European Journal of Cancer, 2013, 49, 1176-1186.	1.3	15
96	Pathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?. Current Urology, 2013, 7, 24-27.	0.4	0
97	Comparison of visual and automated assessment of microvessel density and their impact on outcome in primary operable invasive ductal breast cancer. Human Pathology, 2013, 44, 1688-1695.	1.1	12
98	A Prospective Study of the Role of Inflammation in Bladder Cancer. Current Urology, 2013, 6, 189-193.	0.4	16
99	The Epidemiology and Risk Factors for Renal Cancer. Current Urology, 2013, 6, 169-174.	0.4	26
100	The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clinical Pathology, 2013, 13, 31.	1.8	37
101	Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer, 2013, 108, 139-148.	2.9	52
102	Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. International Journal of Molecular Sciences, 2013, 14, 16656-16671.	1.8	13
103	Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia. Urologia Internationalis, 2013, 90, 150-155.	0.6	8
104	The Prognostic Use of Inflammation and Tissue Necrosis in Benign Prostatic Hyperplasia. Urologia Internationalis, 2013, 91, 19-25.	0.6	6
105	The in situ local immune response, tumour senescence and proliferation in colorectal cancer. British Journal of Cancer, 2013, 109, 2207-2216.	2.9	23
106	The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 2013, 109, 1676-1684.	2.9	124
107	Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death and Disease, 2013, 4, e927-e927.	2.7	74
108	Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 2013, 123, 1157-1175.	3.9	75

#	Article	IF	CITATIONS
109	Association of the canonical NF-κB pathway with clinical outcome measures in ER-negative breast cancer Journal of Clinical Oncology, 2013, 31, 588-588.	0.8	0
110	The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. British Journal of Cancer, 2012, 107, 864-873.	2.9	132
111	Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer, 2012, 106, 1453-1459.	2.9	59
112	NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 2012, 107, 1554-1563.	2.9	55
113	Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British Journal of Cancer, 2012, 106, 383-388.	2.9	78
114	The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. British Journal of Cancer, 2012, 106, 1187-1195.	2.9	17
115	The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. British Journal of Cancer, 2012, 106, 702-710.	2.9	40
116	Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 2012, 107, 856-863.	2.9	30
117	Prospective Study of the Role of Inflammation in Renal Cancer. Urologia Internationalis, 2012, 88, 277-281.	0.6	29
118	Is the Presence or Absence of Tumour Necrosis a Significant Predictor of Survival in Renal Cell Cancer?. Urologia Internationalis, 2012, 88, 79-83.	0.6	2
119	Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Frontiers in Oncology, 2012, 2, 168.	1.3	37
120	The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell, 2012, 151, 1185-1199.	13.5	561
121	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. Cancer Research, 2012, 72, 3457-3462.	0.4	518
122	Targeting sphingosine kinase 1 in cancer. Advances in Biological Regulation, 2012, 52, 31-38.	1.4	37
123	The relationship between tumour site, clinicopathological characteristics and cancerâ€specific survival in patients undergoing surgery for colorectal cancer. Colorectal Disease, 2012, 14, 1493-1499.	0.7	52
124	Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human Pathology, 2012, 43, 1491-1500.	1.1	16
125	The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. Cancer Treatment Reviews, 2012, 38, 943-955.	3.4	40
126	Sphingosine 1-phosphate signalling in cancer. Biochemical Society Transactions, 2012, 40, 94-100.	1.6	109

8

#	Article	IF	CITATIONS
127	Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomarkers, 2012, 10, 91-99.	0.8	11
128	SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Molecular Medicine, 2012, 4, 776-790.	3.3	46
129	The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?. Journal of Cancer Research and Clinical Oncology, 2012, 138, 723-728.	1.2	22
130	Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology, 2012, 61, 283-292.	1.6	26
131	Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology, 2012, 61, 675-684.	1.6	25
132	Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. Journal of Cancer Research and Clinical Oncology, 2012, 138, 327-332.	1.2	13
133	Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. British Journal of Cancer, 2011, 104, 1920-1928.	2.9	70
134	Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens. Cancer Biomarkers, 2011, 8, 1-9.	0.8	2
135	Interrelationships between Tumor Proliferative Activity, Leucocyte and Macrophage Infiltration, Systemic Inflammatory Response, and Survival in Patients Selected for Potentially Curative Resection for Gastroesophageal Cancer. Annals of Surgical Oncology, 2011, 18, 2604-2612.	0.7	22
136	GRP78 upâ€regulation is associated with androgen receptor status, Hsp70–Hsp90 client proteins and castrateâ€resistant prostate cancer. Journal of Pathology, 2011, 223, 81-87.	2.1	53
137	Heregulin Expression and Prognosis in Prostate Adenocarcinoma. Urologia Internationalis, 2011, 87, 363-368.	0.6	4
138	HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proceedings of the United States of America, 2011, 108, 16392-16397.	3.3	51
139	Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer and Prostatic Diseases, 2011, 14, 122-128.	2.0	29
140	Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. British Journal of Cancer, 2011, 105, 1362-1369.	2.9	26
141	Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opinion on Investigational Drugs, 2010, 19, 605-614.	1.9	33
142	Molecular alterations in <i>AKT1</i> , <i>AKT2</i> and <i>AKT3</i> detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-211.	1.6	41
143	Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. British Journal of Cancer, 2010, 102, 1503-1510.	2.9	12
144	Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. British Journal of Cancer, 2010, 103, 899-909.	2.9	61

#	Article	IF	CITATIONS
145	Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. British Journal of Cancer, 2010, 103, 1831-1834.	2.9	10
146	Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells. Molecular and Cellular Biology, 2010, 30, 3827-3841.	1.1	94
147	Sphingosine 1-Phosphate Receptor 4 Uses HER2 (ERBB2) to Regulate Extracellular Signal Regulated Kinase-1/2 in MDA-MB-453 Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 35957-35966.	1.6	72
148	Is Src a Viable Target for Treating Solid Tumours?. Current Cancer Drug Targets, 2010, 10, 683-694.	0.8	16
149	High Expression of Sphingosine 1-Phosphate Receptors, S1P1 and S1P3, Sphingosine Kinase 1, and Extracellular Signal-Regulated Kinase-1/2 Is Associated with Development of Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Patients. American Journal of Pathology, 2010, 177, 2205-2215.	1.9	156
150	A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant Growth. Cancer Research, 2009, 69, 2305-2313.	0.4	763
151	Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2009, 15, 3540-3549.	3.2	147
152	Is the biology of breast cancer changing? A study of hormone receptor status 1984–1986 and 1996–1997. British Journal of Cancer, 2009, 100, 807-810.	2.9	23
153	Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. British Journal of Cancer, 2009, 100, 680-683.	2.9	93
154	Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. Clinical Cancer Research, 2009, 15, 1487-1495.	3.2	71
155	Is Expression or Activation of Src Kinase Associated with Cancer-Specific Survival in ER-, PR- and HER2-Negative Breast Cancer Patients?. American Journal of Pathology, 2009, 175, 1389-1397.	1.9	45
156	Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene, 2008, 27, 2978-2988.	2.6	72
157	Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. British Journal of Cancer, 2008, 98, 1094-1101.	2.9	79
158	Is PTEN loss associated with clinical outcome measures in human prostate cancer?. British Journal of Cancer, 2008, 99, 1296-1301.	2.9	123
159	Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. British Journal of Cancer, 2008, 99, 1769-1774.	2.9	36
160	The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU International, 2008, 102, 756-761.	1.3	49
161	Expression of Tumor Necrosis Factor α Converting Enzyme in Endocrine Cancers. American Journal of Clinical Pathology, 2008, 129, 735-743.	0.4	9
162	An Increase in N-Ras Expression is Associated with Development of Hormone Refractory Prostate Cancer in a Subset of Patients. Disease Markers, 2008, 24, 157-165.	0.6	8

#	Article	IF	CITATIONS
163	Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. British Journal of Cancer, 2007, 97, 378-383.	2.9	110
164	Bad expression influences time to androgen escape in prostate cancer. BJU International, 2007, 100, 691-696.	1.3	16
165	Editorial Comment on: Increased Expression of Tumor-Associated Trypsin Inhibitor, TATI, in Prostate Cancer and in Androgen-Independent 22Rv1 Cells. European Urology, 2007, 52, 1680-1681.	0.9	0
166	The role of SRC family kinases in prostate cancer. Translational Oncogenomics, 2007, 2, 67-77.	1.7	9
167	Observer variation in immunohistochemical analysis of protein expression, time for a change?. Histopathology, 2006, 48, 787-794.	1.6	214
168	The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2006, 12, 123-130.	3.2	93
169	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU International, 2005, 95, 1320-1326.	1.3	118
170	The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU International, 2005, 95, 1327-1335.	1.3	113
171	The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU International, 2005, 96, 62-66.	1.3	13
172	Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate, 2005, 64, 101-107.	1.2	42
173	Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. Journal of Pathology, 2005, 205, 522-529.	2.1	52
174	Microdissection and Extraction of DNA From Archival Tissue. , 2004, 97, 071-076.		1
175	The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. Journal of Pathology, 2004, 204, 153-158.	2.1	65
176	HER2 and COX2 expression in human prostate cancer. European Journal of Cancer, 2004, 40, 50-55.	1.3	81
177	Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. British Journal of Cancer, 2003, 89, 552-556.	2.9	380
178	Mutation and Polymorphism Detection: A Technical Overview. , 2003, 226, 287-294.		2
179	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, 226, 301-308.		1
180	Detection of Microsatellite Instability and Loss of Heterozygosity Using DNA Extracted from Formalin-Fixed Paraffin-Embedded Tumor Material by Fluorescence-Based Multiplex Microsatellite PCR. , 2003, , 301-308.		0

#	Article	IF	CITATIONS
181	Recurrence in Bladder Cancer: A Molecular Dead End?. Current Genomics, 2003, 4, 417-434.	0.7	Ο
182	Gene amplifications associated with the development of hormone-resistant prostate cancer. Clinical Cancer Research, 2003, 9, 5271-81.	3.2	144
183	Routine Acid Decalcification of Bone Marrow Samples Can Preserve DNA for FISH and CGH Studies in Metastatic Prostate Cancer. Journal of Histochemistry and Cytochemistry, 2002, 50, 113-115.	1.3	48
184	14 Role of androgen receptor gene amplification and protein expression in hormone refractory prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 423-430.	0.0	0
185	The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. BJU International, 2002, 90, 573-578.	1.3	16
186	Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. Journal of Pathology, 2002, 196, 380-385.	2.1	35
187	Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. Journal of Pathology, 2002, 198, 237-244.	2.1	83
188	Direct Kinase Assay Screening for Inhibitors of MAP Kinase. , 2001, 39, 583-588.		0
189	Phosphotyrosine Kinase Assays as a Prescreen for Inhibitors of EGFr. , 2001, 39, 577-581.		0
190	Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU International, 2001, 88, 633-637.	1.3	40
191	Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. British Journal of Cancer, 2001, 85, 1894-1899.	2.9	21